Breast Neoplasms Clinical Trials in Charlotte, North Carolina

5 studies are recruiting for breast neoplasms in Charlotte, North Carolina right now. Each one is listed on ClinicalTrials.gov, the public registry the research teams themselves file with. TrialBoost is not a doctor, a research site, or a study sponsor: the research team decides who takes part.

Search these by distance from you

Studies now recruiting

1. ROSETTA Breast-01: The Effects and Safety of Pumitamig in Patients With Triple-Negative Breast Cancer

   This is a Phase III trial where participants will be randomized to two treatment groups, which means participants will be assigned by equal chance to a treatment group. This trial will be double-blinded, which means neither the participants nor the trial doctors will know which of the two treatment…

   Stage

   Phase 3

   Ages

   18 and older

   Site

   Oncology Specialists of Charlotte Pa, Charlotte, North Carolina

   Locations

   202 in total

   Run by

   BioNTech SE

   See if you can join NCT07173751 on ClinicalTrials.gov

2. A Study of Sacituzumab Tirumotecan (MK-2870) as a Single Agent and in Combination With Pembrolizumab (MK-3475) Versus Treatment of Physician's Choice in Participants With HR+/HER2- Unresectable Locally Advanced or Metastatic Breast Cancer (MK-2870-010)

   The purpose of this study is to compare sacituzumab tirumotecan as a single agent, and in combination with pembrolizumab, versus Treatment of Physician's Choice (TPC) in participants with hormone receptor positive/human epidermal growth factor receptor-2 negative (HR+/HER2-) unresectable locally ad…

   Stage

   Phase 3

   Ages

   18 and older

   Site

   Levine Cancer Institute ( Site 0014), Charlotte, North Carolina

   Locations

   259 in total

   Run by

   Merck Sharp & Dohme LLC

   See if you can join NCT06312176 on ClinicalTrials.gov

3. Signatera-Guided CDK4/6 Inhibitor Therapy in Breast Cancer

   The purpose of this study is to evaluate the efficacy and safety of ctDNA-guided initiation of CDK4/6 inhibitor therapy using the Signatera™ Designed on Genome test (referred to as "Signatera Genome") in participants with intermediate-risk HR+/HER2- early-stage breast cancer. Based on ctDNA test re…

   Stage

   Not phased

   Ages

   18 and older

   Site

   Atrium Levine Cancer Institute, Charlotte, North Carolina

   Locations

   49 in total

   Run by

   Natera, Inc.

   See if you can join NCT07214532 on ClinicalTrials.gov

4. A Clinical Study of Patritumab Deruxtecan to Treat Breast Cancer (MK-1022-016)

   Researchers are looking for other ways to treat breast cancer (BC) that is hormone receptor-positive and human epidermal growth factor receptor 2-negative (HR+/HER2-) and either unresectable locally advanced or metastatic. * HR positive (HR+) means the cancer cells have proteins that attach to estr…

   Stage

   Phase 3

   Ages

   18 and older

   Site

   Novant Health Cancer Institute ( Site 0019), Charlotte, North Carolina

   Locations

   199 in total

   Run by

   Merck Sharp & Dohme LLC

   See if you can join NCT07060807 on ClinicalTrials.gov

5. A Long-term Treatment Extension Study of Niraparib in Participants Who Completed a Prior GlaxoSmithKline/TESARO-sponsored Niraparib Study

   This is a global extension study to provide continued access to niraparib and further characterize the long-term safety of niraparib treatment in participants who are currently receiving treatment with niraparib within GlaxoSmithKline/TESARO-sponsored studies (NCT01847274, NCT02354586, NCT01905592,…

   Stage

   Phase 2

   Ages

   18 and older

   Site

   GSK Investigational Site, Charlotte, North Carolina

   Locations

   25 in total

   Run by

   GlaxoSmithKline

   See if you can join NCT04641247 on ClinicalTrials.gov